reported that DOPA is superior to FDG in detecting and localizing lesions in patients with recurrent MTC, especially in those with negative results on other imaging modalities and with Ctn ≥150 pg/mL or CEA ≥5 ng/mL. This evidence concerns the gene CEACAM5 and medullary thyroid gland carcinoma.